Tempest Therapeutics Inc (TPST)

06:09 AM

Tempest Therapeutics Inc. Stock Analysis and ForecastMassive wealth growth - Jammu Links News

06:09 AM

01:46 AM

Is Tempest Therapeutics Inc. a good long term investmentExceptional financial outcomes - Jammu Links News

01:46 AM

Jul 18, 2025

What analysts say about Tempest Therapeutics Inc. stockPowerful growth strategies - Jammu Links News

Jul 18, 2025

Jul 18, 2025

Is Tempest Therapeutics Inc. stock a growth or value playSmart High Yield Swing Trades - Newser

Jul 18, 2025

Jul 18, 2025

What drives Tempest Therapeutics Inc. stock priceHigh-yield capital appreciation - Jammu Links News

Jul 18, 2025

Jul 15, 2025

Why Tempest Therapeutics Inc. stock attracts strong analyst attentionPrecision Entry Strategy - Newser

Jul 15, 2025

Jul 15, 2025

What makes Tempest Therapeutics Inc. stock price move sharplyFree Access to Community - Newser

Jul 15, 2025

Jul 15, 2025

How Tempest Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser

Jul 15, 2025

Jul 09, 2025

Head-To-Head Contrast: Tempest Therapeutics (NASDAQ:TPST) vs. Relmada Therapeutics (NASDAQ:RLMD) - Defense World

Jul 09, 2025

Jul 05, 2025

Tempest Therapeutics (NASDAQ:TPST) Trading Up 0.2% – Here’s Why - Defense World

Jul 05, 2025

Jul 02, 2025

Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment - TipRanks

Jul 02, 2025

Jun 30, 2025

Tempest Receives Clearance to Proceed with Pivotal Trial of - GlobeNewswire

Jun 30, 2025

Jun 14, 2025

Millennium Management LLC Acquires Shares of 189,506 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Jun 14, 2025

Jun 12, 2025

Tempest Therapeutics Secures $4.1M in Direct Offering - TipRanks

Jun 12, 2025

Jun 12, 2025

SEC Form 424B5 filed by Tempest Therapeutics Inc. - Quantisnow

Jun 12, 2025

Jun 12, 2025

Form 424B5 Tempest Therapeutics, - StreetInsider

Jun 12, 2025

Jun 11, 2025

Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor - Nasdaq

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics (TPST) Announces New Stock Purchase Agreeme - GuruFocus

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics ends ATM prospectus with Jefferies By Investing.com - Investing.com Canada

Jun 11, 2025

Jun 11, 2025

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - The Manila Times

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock - Nasdaq

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics announces $4.6 million registered direct offering - Investing.com

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics ends ATM prospectus with Jefferies - Investing.com

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025SEC Filing - MarketScreener

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics (TPST) Announces New Stock Purchase Agreement | TPST Stock News - GuruFocus

Jun 11, 2025

Jun 09, 2025

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 09, 2025

Jun 09, 2025

Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews

Jun 09, 2025

Jun 06, 2025

Tempest Therapeutics Shifts Executives to Consulting Roles - TipRanks

Jun 06, 2025

Jun 05, 2025

Tempest Therapeutics stock rises on EMA Orphan Drug Designation By Investing.com - Investing.com South Africa

Jun 05, 2025

Jun 05, 2025

Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com

Jun 05, 2025

Jun 05, 2025

Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com

Jun 05, 2025

Jun 05, 2025

Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq

Jun 05, 2025

Jun 05, 2025

TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus

Jun 05, 2025

Jun 05, 2025

Tempest Receives Orphan Drug Designation from the European - GlobeNewswire

Jun 05, 2025

Jun 05, 2025

Breakthrough Liver Cancer Drug Shows 6-Month Survival Benefit, Secures Crucial EU and FDA Support - Stock Titan

Jun 05, 2025

May 23, 2025

Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025

May 19, 2025

HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World

May 19, 2025

May 16, 2025

Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025

May 14, 2025

TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus

May 14, 2025

May 14, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 14, 2025

May 13, 2025

Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com

May 13, 2025

May 13, 2025

Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq

May 13, 2025

May 13, 2025

FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan

May 13, 2025

May 11, 2025

Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 11, 2025